Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]
In development
Reference number: GID-TA10404
Expected publication date: TBC
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of avelumab for previously treated platinum-resistant ovarian cancer ID1497 We have recently invited stakeholders to respond to a written consultation on the draft scope.
The company that markets avelumab has advised that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information the Institute will not be progressing with the scoping exercise.
If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar on (44 (0)20 7045 2239 or via email on michelle.adhemar@nice.org.uk)